一氧化氮（NO）在肿瘤治疗中显示出巨大潜力，精确可控NO释放平台的开发仍需探索。在此，提出了一种微流体电喷雾策略，用于制造封装NO供体（S-亚硝基谷胱甘肽，GSNO）以及黑磷（BP）和化疗药物阿霉素（DOX）的水凝胶微球，作为肿瘤治疗的微载体。基于BP优异的光热性能和GSNO的热敏感性，微载体表现出近红外光（NIR）响应的NO释放行为。此外，微载体的光热性能加速了DOX的释放。这些都使得微载体通过结合NO疗法、光热疗法和化疗等多种治疗策略具有优异的肿瘤杀伤效果。此外，研究表明，NIR响应型NO递送微载体可以显着抑制肿瘤生长，并且在体内没有明显的副作用。因此，人们相信新型近红外响应型 NO 微载体是临床肿瘤治疗应用中很有前途的候选者。© 2023 作者。 Wiley‐VCH GmbH 代表中国科学院大学温州研究院出版的《智慧医疗》。

Nitric oxide (NO) has shown great potential in tumor therapy, and the development of a platform for precise and controllable NO release still needs to be explored. Herein, a microfluidic electrospray strategy is proposed for the fabrication of hydrogel microspheres encapsulating NO donors (S-nitrosoglutathione, GSNO) together with black phosphorus (BP) and chemotherapeutic doxorubicin (DOX) as microcarriers for tumor therapy. Based on the excellent photothermal property of BP and thermal sensitivity of GSNO, the microcarriers exhibit a near-infrared light (NIR)-responsive NO release behavior. Besides, the photothermal performance of the microcarriers accelerates the release of DOX. All these contribute to the excellent tumor-killing effect of the microcarriers by combining multiple therapeutic strategies including NO therapy, photothermal therapy, and chemotherapy. Moreover, it was demonstrated that the NIR-responsive NO delivery microcarriers could significantly inhibit tumor growth without apparent side effects in vivo. Therefore, it is believed that the novel NIR-responsive NO microcarriers are promising candidates in clinical tumor therapy applications.© 2023 The Authors. Smart Medicine published by Wiley‐VCH GmbH on behalf of Wenzhou Institute, University of Chinese Academy of Sciences.